The life science group Sartorius and UK-based start-up SPARTA Biodiscovery have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles for bio-pharmaceutical drugs.
Revvity and Element Biosciences, the developer of the AVITI System [1], a genomic sequencing platform, will collaborate to introduce workflow solutions that are more efficient for genomic analysis of samples.
Rockville, Maryland, US-based Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, has acquired VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS’ 160+ staff members manage and monitor vaccine clinical trial activities throughout Latin America.
Biosynth, a supplier of critical materials to the life science industry, has acquired Pepceuticals, a UK producer of synthetic peptides with multi-kilogramme GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply.
SpliceBio, a Barcelona, Spain-based genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has signed an exclusive collaboration and licensing agreement with Philadelphia, Pennsylvania-based Spark Therapeutics to utilize SpliceBio’s proprietary protein splicing platform to develop a gene therapy for an undisclosed inherited retinal disease.
Gilead Sciences has entered into a 12-year partnership with Assembly Biosciences, a biotechnology company developing antiviral therapeutics targeting serious viral diseases. The partnership, announced 17 October, aims to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D […]
Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, has closed an additional US$10 million of its Series A financing, bringing the total raised to $46 million in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical […]
Yamaha Motor Co., Ltd. has established Tuning Fork Bio Inc. in Delaware, USA, which will analyze the antibodies in blood to better visualize people’s health conditions through its antibody profiling business. The main target markets for this new company are the U.S. and Japan.
In a deal potentially worth up to US$22 billion, Merck (known as MSD outside of the United States and Canada) has entered into a collaboration agreement with Japan-based Daiichi Sankyo to co-develop and co-commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd).
Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
